Scott Andrew Smith - Net Worth and Insider Trading
Scott Andrew Smith Net Worth
The estimated net worth of Scott Andrew Smith is at least $488,986 dollars as of 2024-12-28. Scott Andrew Smith is the See Remarks of Celgene Corp and owns about 2,325 shares of Celgene Corp (CELG) stock worth over $251,658. Scott Andrew Smith is the President of BioAtla Inc and owns about 345,656 shares of BioAtla Inc (BCAB) stock worth over $220,529. Scott Andrew Smith is also the Director of Spring Bank Pharmaceuticals Inc and owns about 3,471 shares of Spring Bank Pharmaceuticals Inc (SBPH) stock worth over $16,800. Details can be seen in Scott Andrew Smith's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Scott Andrew Smith has not made any transactions after 2021-12-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Scott Andrew Smith
Scott Andrew Smith Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Scott Andrew Smith owns 7 companies in total, including Spring Bank Pharmaceuticals Inc (SBPH) , Titan Pharmaceuticals Inc (TTNP) , and F-star Therapeutics Inc (FSTX) among others .
Click here to see the complete history of Scott Andrew Smith’s form 4 insider trades.
Insider Ownership Summary of Scott Andrew Smith
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SBPH | Spring Bank Pharmaceuticals Inc | 2020-06-24 | director |
| TTNP | Titan Pharmaceuticals Inc | 2017-01-02 | director |
| FSTX | F-star Therapeutics Inc | 2018-08-15 | director |
 | | 2021-12-02 | director & President |
| | 2022-07-29 | director |
| | 2022-12-29 | director |
| | 2022-07-29 | director |
Scott Andrew Smith Latest Holdings Summary
Scott Andrew Smith currently owns a total of 3 stocks. Among these stocks, Scott Andrew Smith owns 2,325 shares of Celgene Corp (CELG) as of August 1, 2014, with a value of $251,658 and a weighting of 51.47%. Scott Andrew Smith owns 345,656 shares of BioAtla Inc (BCAB) as of December 2, 2021, with a value of $220,529 and a weighting of 45.1%. Scott Andrew Smith also owns 3,471 shares of Spring Bank Pharmaceuticals Inc (SBPH) as of June 28, 2019, with a value of $16,800 and a weighting of 3.44%.
Latest Holdings of Scott Andrew Smith
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CELG | Celgene Corp | 2014-08-01 | 2,325 | 108.24 | 251,658 |
| BCAB | BioAtla Inc | 2021-12-02 | 345,656 | 0.64 | 220,529 |
| SBPH | Spring Bank Pharmaceuticals Inc | 2019-06-28 | 3,471 | 4.84 | 16,800 |
Holding Weightings of Scott Andrew Smith
Scott Andrew Smith Form 4 Trading Tracker
According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 0 shares on August 1, 2014, which brought Scott Andrew Smith around $0.
According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 5 transactions in BioAtla Inc (BCAB) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in BioAtla Inc is the sale of 4,090 shares on December 2, 2021, which brought Scott Andrew Smith around $91,084.
According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 0 transactions in Spring Bank Pharmaceuticals Inc (SBPH) over the past 5 years. The most-recent trade in Spring Bank Pharmaceuticals Inc is the acquisition of 3,000 shares on June 28, 2019, which cost Scott Andrew Smith around $49,080.
Insider Trading History of Scott Andrew Smith
- 1
Scott Andrew Smith Trading Performance
GuruFocus tracks the stock performance after each of Scott Andrew Smith's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott Andrew Smith is -15.18%. GuruFocus also compares Scott Andrew Smith's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott Andrew Smith within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Scott Andrew Smith's insider trading performs compared to the benchmark.
Performance of Scott Andrew Smith
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.6 | | | | | |
| Relative Return to S&P 500(%) | 17.74 | | | | | |
Scott Andrew Smith Ownership Network
Scott Andrew Smith Owned Company Details
What does Spring Bank Pharmaceuticals Inc do?
Who are the key executives at Spring Bank Pharmaceuticals Inc?
Scott Andrew Smith is the director of Spring Bank Pharmaceuticals Inc. Other key executives at Spring Bank Pharmaceuticals Inc include VP of Finance and Treasurer Lori Firmani , director & President and CEO Martin J Driscoll , and Chief Scientific Officer Radhakrishnan P. Iyer .
Spring Bank Pharmaceuticals Inc (SBPH) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Spring Bank Pharmaceuticals Inc (SBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.
Spring Bank Pharmaceuticals Inc Insider Transactions
Scott Andrew Smith Mailing Address
Above is the net worth, insider trading, and ownership report for Scott Andrew Smith. You might contact Scott Andrew Smith via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
